Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
Jeremy S. Abramson(Massachusetts General Hospital), Andrew M. Evens(Rutgers, The State University of New Jersey), Sonali M. Smith(University of Chicago), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Steven T. Rosen(Unknown), Tatyana Feldman(Hackensack University Medical Center), Eric S. Winer(Providence College), Aimee Kroll‐Desrosiers(University of Massachusetts Chan Medical School), Jorge J. Castillo(Dana-Farber Cancer Institute), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), André Goy(Hackensack University Medical Center), Chadi Nabhan(University of Chicago), R. Nath(University of Massachusetts Chan Medical School), Frederick Lansigan(Dartmouth College), Bruce A. Woda(University of Massachusetts Chan Medical School), Lori Muffly(Stanford University)
Cited by 138
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|New England Journal of Medicine|2018|1.1k